Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today highlighted updated results from its ongoing Phase...

Today during the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, presenters of three studies will highlight how recent technological developments are...

Novartis announced results of a retrospective, real-world evidence study in patients with immune thrombocytopenia (ITP) treated with Promacta® (eltrombopag), compared to other second-line...

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today announced that the...

Petra Pharma Corporation, a drug development company focused on novel therapies that modulate phosphoinositide (PI) signaling pathways, today presented preclinical data in an oral presentation at...

Novartis today announced longer-term analyses of both ELIANA and JULIET, the pivotal clinical trials of Kymriah (tisagenlecleucel) in children and young adult patients with relapsed or refractory...

RogCon Biosciences (RogCon), a biotechnology company focused on discovering and developing novel therapeutics for children suffering from SCN2A mutations, today announced preclinical data in a...

100% overall and 80% complete response rate in 10 patients with relapsed or refractory follicular lymphoma treated with 5 mg or more of REGN1979 Plan to initiate in 2019 a potentially...

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced preclinical data presented at the 2018 American Society of...

Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today presented new data from the ongoing Phase 2 Zella...